Eiropas Savienība - latviešu - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobīnūrija, paroksizmāla - imūnsupresanti - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminoskābju metabolisms, iedzimtas kļūdas - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.